SPA70 is an orally available, selective, competitive antagonist of the human pregnane X receptor (hPXR) (IC50=540 nM), which blocks the hPXR nuclear receptor signaling pathway and its mediated transcriptional activation of drug metabolizing enzymes (e.g., CYP3A4, MDR1). SPA70 exhibits low toxicity in both in vitro and in vivo models and can be used to study hPXR-mediated cancer drug resistance and liver injury[1][2][3].
Molecular Weight:
415.51
Purity:
99
CAS Number:
[931314-31-7]
Formula:
C21H25N3O4S
Target:
Pregnane X Receptor (PXR)
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
